Industry: Healthcare and Medical News
CorMatrix Cardiovascular, Inc. develops and delivers implantable biomaterial devices that harness the body’s innate ability to repair damaged cardiac and vascular tissues. CorMatrix extracellular matrix (ECM®) acts as a scaffold into which a patient’s own cells migrate and integrate. Natural wound healing mechanisms are stimulated and remodel to form a strong, permanent tissue repair. CorMatrix® leaves behind no foreign material, allowing surgeons to restore the native anatomy of tissues in need of repair. Headquartered in Roswell, Georgia, the Company is currently researching and commercializing its platform technology known as CorMatrix® ECM® for a variety of cardiovascular and other indications. CorMatrix has U.S. clearance and European registration (with a CE Mark) for its ECM® technology. Since its launch in 2006, CorMatrix® ECM® Technology has been used at more than 975 hospitals across the U.S. and has been implanted in over 145,000 cardiovascular procedures. Visit cormatrix.com for additional information.